5914 Results

People

  1. Ladanyi
    Ladanyi
  2. Solit
    Solit
  3. Levine
    Levine
  4. Berger
    Berger
  5. Schultz
    Schultz
  6. Arcila
    Arcila
  7. Hakimi
    Hakimi
  8. Chandarlapaty
    Chandarlapaty
  9. Zehir
    Zehir
  10. Mellinghoff
    Mellinghoff

Groups

  1. Human Oncology and Pathogenesis Program (5914)
  2. GSK Faculty (5697)
  3. Department of Medicine (4259)
  4. Department of Pathology and Laboratory Medicine (3037)
  5. Tow Center for Developmental Oncology (TCDO) (2613)
  6. Solid Tumor Oncology Division (2600)
  7. Sloan Kettering Institute Postdocs (1984)
  8. Hematologic Malignancies, Division of (1879)
  9. Center for Hematologic Malignancies (1845)
  10. Center for Molecular Imaging and Biotechnology (CMIB) (1744)
  1. "Human Oncology and Pathogenesis Program"
Formats
  1. Journal Article (2984)
  2. Meeting Abstract (2527)
  3. Review (137)
  4. Editorial (106)
  5. Book Section (54)
  6. Research Letter (41)
  7. Guidelines (18)
  8. Correspondence (16)
  9. Miscellaneous (15)
  10. Conference Paper (13)
  11. Book Whole (3)
Groups
  1. Human Oncology and Pathogenesis Program (5914)
  2. GSK Faculty (5697)
  3. Department of Medicine (4259)
  4. Department of Pathology and Laboratory Medicine (3037)
  5. Tow Center for Developmental Oncology (TCDO) (2613)
  6. Solid Tumor Oncology Division (2600)

More Groups

People
  1. Marc Ladanyi (1327)
  2. David Solit (779)
  3. Ross Levine (774)
  4. Michael Berger (765)
  5. Nikolaus Schultz (486)
  6. Maria Arcila (426)

More People

Years
  1. 2025 (120)
  2. 2024 (359)
  3. 2023 (402)
  4. 2022 (451)
  5. 2021 (380)
  6. 2020 (457)

More Years

Publications
  1. Journal of Clinical Oncology (636)
  2. Blood (495)
  3. Cancer Research (412)
  4. Modern Pathology (299)
  5. Clinical Cancer Research (268)
  6. Laboratory Investigation (263)

More Publications

Publishers
  1. American Association for Cancer Research (871)
  2. Nature Publishing Group (758)
  3. American Society of Clinical Oncology (702)
  4. American Society of Hematology (541)
  5. Elsevier Inc. (420)
  6. Nature Research (312)

More Publishers

Results (5914)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • MET in pleural mesothelioma: Mutational screening, phosphorylation status, and sensitivity to MET inhibition
    Meeting Abstract

    Shimizu, S.; Lopez-Rios, F.; Olshen, A. B.; Rusch, V.; Ladanyi, M.
    Modern Pathology (2007)

    Fulltext@MSK | Save
  • MET in pleural mesothelioma: Mutational screening, phosphorylation status, and sensitivity to MET inhibition
    Meeting Abstract

    Shimizu, S.; Lopez-Rios, F.; Olshen, A. B.; Rusch, V.; Ladanyi, M.
    Laboratory Investigation (2007)

    Fulltext@MSK | Save
  • Targeted therapies - The next wave
    Meeting Abstract

    Sawyers, C. L.
    Cancer Investigation (2007)

    Fulltext@MSK | Save
  • BRAF mutation predicts MEK-dependence in non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Pratilas, C. A.; Halilovic, E.; Persaud, Y.; Sawai, A.; Grbovic-Huezo, O.; Janakiraman, M.; Rosen, N.; Solit, D. B.
    Molecular Cancer Therapeutics (2007)

    Fulltext@MSK | Save
  • PHA-739358, an aurora kinase inhibitor, induces clinical responses in chronic myeloid leukemia harboring T315I mutations of BCR-ABL
    Meeting Abstract

    Paquette, R. L.; Shah, N. P.; Sawyers, C. L.; Martinelli, G.; John, N.; Chalukya, M.; Rocchetti, M.; Fiocchi, C.; Clomis, S.; Capolongo, L.; more...
    Blood (2007)

    Fulltext@MSK | Save
  • Comprehensive detection of gene fusions in sarcomas and other cancers using exon-level expression data obtained by affymetrix exon arrays
    Meeting Abstract

    Motoi, T.; Socci, N.; Lash, A.; Mertens, F.; Gerald, W.; Ladanyi, M.
    Modern Pathology (2007)

    Fulltext@MSK | Save
  • Comprehensive detection of gene fusions in sarcomas and other cancers using exon-level expression data obtained by affymetrix exon arrays
    Meeting Abstract

    Motoi, T.; Socci, N.; Lash, A.; Mertens, F.; Gerald, W.; Ladanyi, M.
    Laboratory Investigation (2007)

    Fulltext@MSK | Save
  • Tanespimycin (an Hsp90 inhibitor) and trastuzumab is an active combination in patients (pts) with Her2-positive trastuzumab-refractory metastatic breast cancer (MBC): Phase 2 trial
    Meeting Abstract

    Modi, S.; Stopeck, A.; Kinden, H.; Sugarman, S.; Ma, W.; Solit, D.; Kersey, K.; Johnson, R.; Hannah, A. L.; Hudis, C.
    Breast Cancer Research and Treatment (2007)

    Fulltext@MSK | Save
  • Biomarkers of brain tumors to EGFR-TKI
    Meeting Abstract

    Mellinghoff, I.
    EJC Supplements (2007)

    Fulltext@MSK | Save
  • EGFR and KRAS mutations are molecular predictors of survival in resected lung adenocarcinoma
    Meeting Abstract

    Marks, J. L.; Broderick, S.; Seshan, V. E.; Zakowski, M. F.; Li, A.; Wilson, R.; Kris, M. G.; Ladanyi, M.; Rusch, V. W.; Pao, W.
    Journal of Thoracic Oncology (2007)

    Fulltext@MSK | Save